Pfizer, Novartis evaluate combo therapies for NASH
Executive Summary
Pfizer Inc. and Novartis AG have agreed to collaborate on one or more combination therapies for the treatment of nonalcoholic steatohepatitis (NASH).
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice